Furoato de fluticasona

ATC code

R01AD12

Therapeutic class

Nasal corticosteroid · Corticosteroid for topical use

Forms

nasal spray, suspension

Brand names

Avamys (EU) · Veramyst (US) · Allergodil (DE)

Overall confidence

high

Regulatory sources consulted

Approved indications

Treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and over) and children (6-11 years).

Contraindications

Absolute

Hypersensitivity to the active substance or to any of the excipients.

Clinical warnings

Systemic effects: Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. — EMA
Major warning · Growth retardation: Regular monitoring of height is recommended in children receiving prolonged treatment with nasal corticosteroids. — EMA
Visual disturbance: Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, an ophthalmologist referral should be considered. — EMA

Drug interactions

HighRitonavirJ05AE03
Mechanism: Potent inhibition of CYP3A4, significantly increasing fluticasone furoate plasma concentration and the risk of systemic corticosteroid effects.
Recommendation: Co-administration is not recommended due to the risk of increased systemic corticosteroid effects.
EMA SPC
ModerateKetoconazoleJ02AB02
Mechanism: Inhibition of CYP3A4, which may increase systemic exposure to fluticasone furoate.
Recommendation: Use with caution. Monitor for potential systemic corticosteroid adverse effects.
EMA SPC

Adverse events

Common (≥1%)

epistaxis · headache · nasal ulceration

Rare but serious

hypersensitivity reactions (anaphylaxis, angioedema) · growth retardation (pediatric population) · glaucoma · cataracts · nasal septal perforation

Pregnancy and lactation

Pregnancy: There are no adequate data. Administer only if the expected benefit to the mother is greater than any possible risk to the fetus. Lactation: It is unknown whether it is excreted in human milk; a decision must be made whether to discontinue breast-feeding or to discontinue therapy.